TG Therapeutics gains on ublituximab data
TG Therapeutics Inc. (NASDAQ:TGTX) said IV ublituximab ( TG-1101) plus once-daily oral Imbruvica ibrutinib led to an overall response rate (ORR) of 90% in 10 evaluable patients in the open-label Phase II UTX-IB-104 trial to treat relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). In seven CLL patients, there were six partial responses (PRs) and one case of stable disease. In three MCL patients, there was one complete response and two PRs. Data were presented at the European Hematology Association meeting in Milan. Additional data are slated to be presented at the American Society of Hematology meeting in December.
In 2012, TG Therapeutics exercised an option to license exclusive, worldwide rights to develop and commercialize ublituximab -- a chimeric mAb against CD20 -- from former parent company LFB S.A. (Les Ulis, France), which spun out TG Therapeutics in November 2010. ...